mitomycin has been researched along with Neoplasm Metastasis, Unknown Primary in 17 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-five patients with metastatic carcinomas of unknown primary site (50 adenocarcinomas) were randomized, after stratification, to treatment with either mitomycin and doxorubicin (MA) or mitomycin, doxorubicin, and cisplatin (MAP)." | 9.06 | Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. ( Eagan, RT; Long, HJ; Rubin, J; Schutt, AJ; Therneau, TM, 1987) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 7.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| "Unresectable intrahepatic cholangiocarcinoma has a poor prognosis, with a median survival of 5 to 8 months without treatment." | 5.37 | Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. ( Albert, M; Christians, K; Fraker, D; Kiefer, MV; McNally, M; Olthoff, K; Pappas, S; Rilling, W; Robertson, M; Soulen, MC; Sun, W, 2011) |
| "Fifty-five patients with metastatic carcinomas of unknown primary site (50 adenocarcinomas) were randomized, after stratification, to treatment with either mitomycin and doxorubicin (MA) or mitomycin, doxorubicin, and cisplatin (MAP)." | 5.06 | Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. ( Eagan, RT; Long, HJ; Rubin, J; Schutt, AJ; Therneau, TM, 1987) |
| "As part of a Phase II chemotherapy trial using mitomycin-C, adriamycin, and vindesine, 57 patients with adenocarcinoma of unknown primary site were assessed for prognostic variables predictive of response and survival." | 3.68 | Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. ( Chapman, D; Fiore, J; Kambhu, SA; Kelsen, DP; Niedzwiecki, D; Rosenbluth, R; Vinciguerra, V, 1990) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 3.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| " The aim of this phase I study was to determine the toxicity profile and the optimal dosage of KW-2149." | 2.68 | Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149. ( Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D, 1995) |
| "Unresectable intrahepatic cholangiocarcinoma has a poor prognosis, with a median survival of 5 to 8 months without treatment." | 1.37 | Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. ( Albert, M; Christians, K; Fraker, D; Kiefer, MV; McNally, M; Olthoff, K; Pappas, S; Rilling, W; Robertson, M; Soulen, MC; Sun, W, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (41.18) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Sugarbaker, PH | 1 |
| Kiefer, MV | 1 |
| Albert, M | 1 |
| McNally, M | 1 |
| Robertson, M | 1 |
| Sun, W | 1 |
| Fraker, D | 1 |
| Olthoff, K | 1 |
| Christians, K | 1 |
| Pappas, S | 1 |
| Rilling, W | 1 |
| Soulen, MC | 1 |
| Nakagawa, Y | 1 |
| Todoroki, T | 1 |
| Koike, N | 1 |
| Kawamoto, T | 1 |
| Assersohn, L | 1 |
| Norman, AR | 1 |
| Cunningham, D | 1 |
| Iveson, T | 1 |
| Seymour, M | 1 |
| Hickish, T | 1 |
| Massey, A | 1 |
| Prior, Y | 1 |
| Hill, ME | 1 |
| Polyzos, A | 1 |
| Koulentianos, E | 1 |
| Tzianoumis, L | 1 |
| Sfikakis, P | 1 |
| Dirix, L | 1 |
| Catimel, G | 1 |
| Koier, I | 1 |
| Provè, A | 1 |
| Schrijvers, D | 1 |
| Joossens, E | 1 |
| De Bruijn, E | 1 |
| Ardiet, C | 1 |
| Evene, E | 1 |
| Dumortier, A | 1 |
| Kan, K | 1 |
| Naitoh, K | 1 |
| Tsuruta, A | 1 |
| Mizuta, N | 1 |
| Ohmori, K | 1 |
| Kawachi, H | 1 |
| Amaike, H | 1 |
| Yanada, M | 1 |
| Ohmori, Y | 1 |
| Ida, K | 1 |
| Kamiya, T | 1 |
| Macdonald, AG | 1 |
| Nicolson, MC | 1 |
| Samuel, LM | 1 |
| Hutcheon, AW | 1 |
| Ahmed, FY | 1 |
| Kerr, DJ | 1 |
| Goldberg, JA | 1 |
| Anderson, JR | 1 |
| Wilmott, N | 1 |
| Whatelely, AT | 1 |
| McArdle, CS | 1 |
| Mckillop, J | 1 |
| Kambhu, SA | 1 |
| Kelsen, DP | 1 |
| Fiore, J | 1 |
| Niedzwiecki, D | 1 |
| Chapman, D | 1 |
| Vinciguerra, V | 1 |
| Rosenbluth, R | 1 |
| Milliken, ST | 1 |
| Tattersall, MH | 1 |
| Woods, RL | 1 |
| Coates, AS | 1 |
| Levi, JA | 1 |
| Fox, RM | 1 |
| Raghavan, D | 1 |
| Treat, J | 1 |
| Falchuk, SC | 1 |
| Tremblay, C | 1 |
| Spielman, M | 1 |
| Woolley, PV | 1 |
| Rouesse, J | 1 |
| Sevin, D | 1 |
| Le Chevalier, T | 1 |
| Pasterz, R | 1 |
| Savaraj, N | 1 |
| Burgess, M | 1 |
| Yumoto, Y | 1 |
| Okuda, T | 1 |
| Kato, Y | 1 |
| Tashima, M | 1 |
| Sawada, H | 1 |
| Yamagishi, M | 1 |
| Uchino, H | 1 |
| van der Gaast, A | 1 |
| Verweij, J | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
| Eagan, RT | 1 |
| Therneau, TM | 1 |
| Rubin, J | 1 |
| Long, HJ | 1 |
| Schutt, AJ | 1 |
5 trials available for mitomycin and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2003 |
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcino | 1995 |
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2002 |
Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; C | 1987 |
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials a | 1987 |
12 other studies available for mitomycin and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile | 2011 |
[A successful combination therapy with resection and infusion chemotherapy for a patient with metastases from cancer of unknown origin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dox | 2003 |
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; H | 1989 |
[A CR case of amylase-producing tumor treated by hyperthermochemotherapy].
Topics: Adenocarcinoma; Amylases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Floxu | 1998 |
[Induced hypertensive chemotherapy with angiotensin II found effective for mediastinal lymph node metastases of unknown origin].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo | 2000 |
The effect of angiotensin II on tumor blood flow and the delivery of microparticulate cytotoxic drugs.
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Colonic Neoplasms; D | 1992 |
Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Hu | 1990 |
Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1989 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1986 |
[A cancer of unknown primary site with diffuse metastasis to the bone marrow treated effectively with FAM combination chemotherapy].
Topics: Anemia, Myelophthisic; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; | 1988 |
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1988 |